Startseite Crystal structure of 9-methyl-3-methylene-1,2,3,9-tetrahydro-4H-carbazol-4-one, C14H13NO
Artikel Open Access

Crystal structure of 9-methyl-3-methylene-1,2,3,9-tetrahydro-4H-carbazol-4-one, C14H13NO

  • Yu-Jing Ke , Peng-Jie Liang , Peng-Cheng Wang , Shao-Hua Xian und Guo-Qiang Li ORCID logo EMAIL logo
Veröffentlicht/Copyright: 3. März 2021

Abstract

C14H13NO, monoclinic, P21/n (no. 14), a = 9.2770(7) Å, b = 8.4582(6) Å, c = 13.4430(12) Å, β = 98.199(8)°, V = 1044.05(14) Å3, Z = 4, Rgt(F) = 0.0484, wRref(F2) = 0.1151, T = 100 K.

CCDC no: 2051198

The molecular structure is shown in the figure. Table 1 contains crystallographic data and Table 2 contains the list of the atoms including atomic coordinates and displacement parameters.

Table 1:

Data collection and handling.

Crystal:Colourless block
Size:0.13 × 0.12 × 0.11 mm
Wavelength:Mo Kα radiation (0.71073 Å)
μ:0.09 mm−1
Diffractometer, scan mode:SuperNova, ω
θmax, completeness:29.5°, >99%
N(hkl)measured, N(hkl)unique, Rint:5167, 2462, 0.028
Criterion for Iobs, N(hkl)gt:Iobs > 2 σ(Iobs), 1972
N(param)refined:154
Programs:CrysAlisPRO [1], SHELX [2]
Table 2:

Fractional atomic coordinates and isotropic or equivalent isotropic displacement parameters (Å2).

AtomxyzUiso*/Ueq
O10.61090 (11)−0.00383 (12)0.24068 (8)0.0211 (3)
N10.46948 (12)0.30457 (14)−0.03918 (9)0.0155 (3)
C20.58035 (15)0.21320 (16)0.00686 (11)0.0153 (3)
C30.71485 (16)0.17327 (18)−0.03569 (12)0.0183 (3)
H3A0.74340.2611−0.07500.022*
H3B0.69840.0815−0.07910.022*
C40.83483 (16)0.13829 (18)0.05277 (12)0.0210 (4)
H4A0.91930.09590.02700.025*
H4B0.86370.23630.08750.025*
C50.78621 (15)0.02261 (17)0.12629 (11)0.0174 (3)
C60.64345 (15)0.05667 (17)0.16308 (11)0.0160 (3)
C70.54889 (15)0.16382 (17)0.10003 (11)0.0153 (3)
C80.40946 (15)0.23055 (17)0.11246 (11)0.0154 (3)
C90.32278 (15)0.22991 (18)0.18935 (12)0.0176 (3)
H90.35010.17210.24790.021*
C100.19524 (16)0.31725 (18)0.17644 (12)0.0205 (4)
H100.13710.31910.22740.025*
C110.15221 (15)0.40280 (18)0.08799 (12)0.0204 (3)
H110.06630.46090.08180.025*
C120.23392 (15)0.40323 (17)0.00979 (12)0.0184 (3)
H120.20390.4580−0.04950.022*
C130.36371 (15)0.31760 (17)0.02408 (11)0.0158 (3)
C140.45844 (16)0.37296 (18)−0.13946 (11)0.0187 (3)
H14A0.55260.4095−0.15110.028*
H14B0.39160.4602−0.14480.028*
H14C0.42390.2942−0.18860.028*
C150.86253 (17)−0.1047 (2)0.15992 (13)0.0223 (4)
H15A0.956 (2)−0.128 (2)0.1372 (14)0.028 (5)*
H15B0.8270 (19)−0.177 (2)0.2101 (14)0.029 (5)*

Source of material

1,2,3,9-Tetrahydro-9-methyl-4H-carbazol-4-one was purchased from

Shanghai Bepharm Science & Technology Co., Ltd., Shanghai, China. 1,2,3,9-Tetrahydro-9-methyl-4H-carbazol-4-one (1.00 g, 5 mmol), dimethylamine hydrochloride (380 mg, 4.6 mmol), paraformaldehyde (150 mg, 5 mmol) and acetic acid (25 ml) were added, and refluxed for 4 h. The reaction was monitored by TLC (PE:EA = 2:1). After the reaction was complete, the reaction solution was cooled to room temperature, water was added to precipitate a solid, and the 9-methyl-3-methylene-1,2,3,9-tetrahydro-4H-carbazol-4-one, a white solid, was obtained by negative-pressure filtration. The title compound was dissolved in hot ethanol. Then the solution was cooled naturally to crystallize at room temperature.

Experimental details

The H atoms were positioned geometrically and were included in the refinement in the riding-model approximation. The crystal structure was solved by direct method and refined with SHELXT [2].

Comment

9-Methyl-3-methylene-1,2,3,9-tetrahydro-4H-carbazol-4-one, an impurity of Ondansetron, belongs to carbazole ketone compouds. Carbazole ketone compouds are important scaffolds for the synthesis of some natural products and bioactive substances [3]. Ondansetron, a serotonin 5-HT3 receptor selective antagonist [4], [5], [6], is effective in preventing acute nausea and vomiting associated with emetogenic chemotherapy and/or radiotherapy in children and is now the most clinically used antiemetic drug [7], [, 8]. Because the impurities in a drug have potential toxicity and biological activity, the characterisation of each impurity is essential for the safety evaluation of the drug. The crystal was obtained by slow evaporation from an ethanol solution.

The title compound possesses a 6/5/6 ring system consisting of the benzene ring, pyrrole ring and cyclohexanone. The bonds lengths of C=C, C—N, C=O and C—C are 1.381(2)–1.411(2), 1.3625(18)–1.4570(19), 1.2374(18), 1.4427(19)–1.537(2) Å, respectively, all of which derived from the title structure are in reasonable ranges [9].


Corresponding author: Guo-Qiang Li, Department of Food Science and Engineering, Foshan University, Foshan, 528231, P. R. China, E-mail:

Award Identifier / Grant number: 21405013

Award Identifier / Grant number: 2016SFKC-43

Award Identifier / Grant number: gg040971

Award Identifier / Grant number: 2016 A030310079

  1. Author contribution: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.

  2. Research funding: Grants from the National Natural Science Foundation of China (No. 21405013), Postgraduate demonstration course construction fundation of Guangdong Education Department (2016SFKC-43), the Fundamental Research Funds for the Central Universities (Grant gg040971), the Natural Science Foundation of Guangdong Province (Grant 2016 A030310079).

  3. Conflict of interest statement: The authors declare no conflicts of interest regarding this article.

References

1. Agilent Technologies. CrysAlisPRO Software System; Agilent Technologies UK Ltd: Oxford, UK, 2015.Suche in Google Scholar

2. Sheldrick, G. M. A short history of SHELX. Acta Crystallogr. 2008, A64, 112–122; https://doi.org/10.1107/s0108767307043930.Suche in Google Scholar

3. Knoelker, H. J., Reddy, K. R. Isolation and synthesis of biologically active carbazole alkaloids. Chem. Rev. 2002, 102, 4303–4428.10.1002/chin.200304238Suche in Google Scholar

4. Mohamed, S. A., Hussam, A. M., Abdallah, S. A., Sarhan, K. A., Shaban, A. M. Ondansetron is an effective alternative to decrease the incidence of postspinal hypotension in healthy subjects undergoing infra-umbilical surgeries compared to combined volume loading and vasoconstrictors: randomized controlled trial. Open access Maced. J. Med. Sci. 2018, 6, 2363–2368; https://doi.org/10.3889/oamjms.2018.491.Suche in Google Scholar

5. Barrett, T. W., Dipersio, D. M., Jenkins, C. A., Jack, M., Mccoin, N. S., Storrow, A. B., Singleton, L. M., Lee, P., Zhou, C., Slovis, C. M. A randomized, placebo-controlled trial of ondansetron, metoclopramide, and promethazine in adults. Am. J. Emerg. Med. 2011, 29, 247–255; https://doi.org/10.1016/j.ajem.2009.09.028.Suche in Google Scholar

6. Doggrell, S. A. Granisetron in the treatment of chemotherapy-induced nausea and vomiting (CINV) is there still a role after comparison with palonosetron. Expet Opin. Pharmacother. 2017, 18, 1019–1026; https://doi.org/10.1080/14656566.2017.1342809.Suche in Google Scholar

7. Culy, C. R., Bhana, N., Plosker, G. L. Ondansetron: a review of its use as an antiemetic in children. Paediatr. Drugs 2001, 3, 441–479; https://doi.org/10.2165/00128072-200103060-00007.Suche in Google Scholar

8. Xu, Q. G., Liu, T. Y., Tian, R. Synthesis and antiemetic activity of 1,2,3,9-tetrahydro-9-methyl-3-(4-substituted-piperazin-1-ylmethyl)-4H- carbazol-4-one derivatives. Front. Chem. China 2009, 4, 63–68; https://doi.org/10.1007/s11458-009-0017-8.Suche in Google Scholar

9. Sonar, V. N., Parkin, S., Crooks, P. A. 3-Ethyl-2-methyl-5-methylene- 6,7-dihydroindol-4(5H)-one. Acta Crystallogr. 2008, E64, o158; https://doi.org/10.1107/s1600536807063076.Suche in Google Scholar

Received: 2020-12-02
Accepted: 2020-12-18
Published Online: 2021-03-03
Published in Print: 2021-05-26

© 2020 Yu-Jing Ke et al., published by De Gruyter, Berlin/Boston

This work is licensed under the Creative Commons Attribution 4.0 International License.

Artikel in diesem Heft

  1. Frontmatter
  2. New Crystal Structures
  3. The crystal structure of bis(μ2-5-chloro-2-oxido-N-(1-oxidoethylidene)benzohydrazonato-κ5N,O,O′:N′,O′′)hexkis(pyridine-κ1N)trinickel(II) - pyridine (1/1), C63H57Cl2N13Ni3O6
  4. Crystal structure of [(μ2-succinato κ3O,O′:O′′)-bis-(5,5,7,12,12,14-hexamethyl-1,4,8,11-tetraazacyclotetradecane)]dinickel(II)] diperchlorate, dihydrate C36H82Cl2N8Ni2O15
  5. Crystal structure of catena-poly[aquabis(3-nitrobenzoato-κ2O:O′)-(μ2-pyrazine-N: N′)cadmium(II)], C18H14N4O9Cd
  6. Crystal structure of 4-(2,2-difluoroethyl)-2,4,6-trimethylisoquinoline-1,3(2H,4H)-dione, C14H15F2NO2
  7. The crystal structure of thioxanthen-9-one-10,10-dioxide, C13H8O3S – a second polymorph
  8. Crystal structure of (E)-2-((2-methoxy-3-pyridyl)methylene)-7-fluoro-3,4-dihydronaphthalen-1(2H)-one, C17H14FNO2
  9. The crystal structure of diaquahydrogen 2,5-dimethylbenzenesulphonate, C8H14O5S
  10. The crystal structure of N-(4-(cyclohexylimino)pent-2-en-2-yl)cyclohexanamine, C17H30N2
  11. The twinned crystal structure of 1,3-phenylenedimethanaminium dibromide, C8H14Br2N2
  12. Crystal structure of 2,4,7,9-tetranitro-10H-benzofuro[3,2-b]indole – dimethyl sulfoxide (1/1), C16H11N5O10S
  13. Crystal structure of 2,6-bis(2-(pyridin-3-yl)ethyl)pyrrolo[3,4-f]isoindole-1,3,5,7(2H,6H)-tetraone, C24H18N4O4
  14. The crystal structure of 3,4-dichlorobenzoic acid chloride, C7H3Cl3O
  15. Crystal structure of 1,1′-(1,4-phenylenebis(methylene))bis(pyridin-1-ium) bis(1,2-dicyanoethene-1,2-dithiolato-k2S:S)zinc(II), C26H18N6ZnS4
  16. Crystal structure of tetrakis(μ-naphthalene-1-carboxylato-κ2O,O′)bis(methanol)copper(II), C46H36Cu2O10
  17. Crystal structure of 9-methyl-3-methylene-1,2,3,9-tetrahydro-4H-carbazol-4-one, C14H13NO
  18. Crystal structure of bis(amino(carbamothioylamino)methaniminium) 3-nitrophthalate monohydrate, C12H19N9O7S2
  19. Crystal structure of 3,3′-(1,2-phenylene-bis(methylene))bis(1-ethyl-1H-imidazol-3-ium) bis(hexafluorophosphate), C18H24F12N4P2
  20. The crystal structure of 5-hydroxy-6,8-dimethoxy-2-methyl-4H-benzo[g]chromen-4-one– rubrofusarin B, C16H14O5
  21. The crystal structure of bis(ethanol-kO)- bis(6-aminopicolinato-k2N,O)manganese(II), C16H22O6N4Mn
  22. The crystal structure of 3,3′-((carbonylbis(azanediyl))bis(ethane-2,1-diyl)) bis(1-methyl-1H-benzo[d]imidazol-3-ium) tetrafluoroborate monohydrate, C21H28N6O3B2F8
  23. Crystal structure of dimethanol-dichlorido-bis( μ2-2-(((1,5-dimethyl-3-oxo-2- phenyl-2,3-dihydro-1H-pyrazol-4-yl)imino)methyl)phenolato- κ4O:O,O′,N)dinickel (II), C20H24ClNiN3O4
  24. The crystal structure of methyl 5-(trifluoromethyl)-1H-pyrrole-2-carboxylate, C7H6F3NO2
  25. Crystal structure of (OC‐6‐13)‐aqua‐tris (3‐bromopyridine‐κ1N)‐bis(trifluoroacetato‐κ1O)cadmium(II) C19H14Br3CdF6N3O5
  26. Crystal structure of methyl (E)-3-(4-(2-ethoxy-2-oxoethoxy)phenyl) acrylate, C14H16O5
  27. Crystal structure of methyl 4-acetoxy-3,5-dimethoxybenzoate, C12H14O6
  28. The crystal structure of 2-(1H-benzimidazol-2-yl)-3-bromo-5-chlorophenol, C13H8BrClN2O
  29. The crystal structure of bis(μ2-5-chloro-N-(2-methyl-1-oxidopropylidene)-2-oxidobenzohydrazonate-κ5N,O,O′:N′,O′′)pentakis(pyridine-κ1N)tricopper(II), C47H45Cl2N9Cu3O6
  30. Synthesis and crystal structure of catena-poly[aqua-bis(nitrato-κ2O:O′)- (μ2-((1 H-imidazol-1-yl)methyl)benzene-κ2 N,N′)-H2O-κ2O]cadmium(II), C14H16N6O7Cd
  31. The crystal structure of pentakis(carbonyl)-{μ-[2,3-bis(sulfanyl)propan-1-olato]}-(triphenylphosphane)diiron (FeFe)C26H21Fe2O6PS2
  32. Crystal structure of ethyl-2-(3-benzoylthioureido)propanoate, C13H16N2O3S
  33. Crystal structure of 2-methoxy-4b,5,14,15-tetrahydro-6H-isoquinolino[2′,1′:1,6] pyrazino[2,3-b]quinoxaline, C19H18N4O
  34. Crystal structure of 2,2′-[ethane-1,2-diylbis(azanylylidenemethylylidene)]bis(6-chlorophenol), C16H14Cl2N2O2
  35. The crystal structure of (Z)-3-((2-(2-(2-aminophenoxy)ethoxy)phenyl)amino)-1-phenylbut-2-en-1-one, C24H24N2O3
  36. The crystal structure of 10-(3,5-di(pyridin-4-yl)phenyl)-10H-phenoxazine dihydrate, C28H23N3O3
  37. Crystal structure of poly[dipoly[aqua-di(µ2-pyrazin-2-olato-κ2N:N′) zinc(II)], C8H8N4O3Zn
  38. Crystal structure of poly[tetra(μ2-cyanido-κ2N:O)-bis(N,N-dimethylformamide-κO)-manganese(II)-platinum(II)], C10H14MnN6O2Pt
  39. The crystal structure of aqua-chlorido-6,6′-((ethane-1,2-diylbis(azaneylylidene))bis(methaneylylidene))bis(2,4-dichlorophenolato-κ4N,N′,O,O′)manganese(III), C16H12Cl5MnN2O3
  40. Crystal structure of [di(µ2-cyanido)-dicyanido-bis(dimethyl sulfoxide-κO)- bis(2,2′-(ethane-1,2-diylbis(azanylylidenemethanylylidene))diphenolato-κ4,N,N′,O,O′)- dimanganese(III)-platinum(II)], C40H40Mn2N8O6PtS2
  41. The crystal structure of (azido)-κ1N-6,6′-((cyclohexane-1,2-diylbis(azanylylidene)) bis(methanylylidene))bis(3-bromophenolato-κ4N,N,O,O)-(methanol)-manganese(III)–methanol(1/1), C22H26Br2MnN5O4
  42. Crystal structure of 7-chloro-N-(4-iodobenzyl)-1,2,3,4-tetrahydroacridin-9-amine, C20H18ClIN2
  43. Crystal structure of catena-poly[(1,4,8,11-tetraazacyclotetradecane-κ4N,N,N,N′′′)-bis(μ2-thiocyanato-κ2N:S)-bis(thiocyanato-κS)-nickel(II)palladium(II)], C14H24N8NiPdS4
  44. Crystal structure of 3-chloro-4-(4-ethylpiperazin-1-yl)aniline monohydrate, C12H20ClN3O
  45. Crystal structure of the 2D coordination polymer poly[diaqua-bis(μ2-3- methoxyisonicotinato-κ2N:O)cobalt(II)] — dimethylformamide (1/1), C20H30CoN4O10
  46. Crystal structure of 4-[(5-chloro-2-hydroxybenzylidene)amino]-3-propyl-1H-1,2,4-triazole-5(4H)-thione, C12H13ClN4OS
  47. Crystal structure of N-(5-(2-(benzyl(1-(4-methoxyphenyl)propan-2-yl)amino)-1-hydroxyethyl)-2-(benzyloxy)phenyl)formamide, C33H36N2O4
  48. Crystal structure of 3-(methoxycarbonyl)-7-oxabicyclo[2.2.1]heptane-2-carboxylic acid, C9H12O5
  49. The crystal structure of 1-((dimethylamino)(3-nitrophenyl)methyl)naphthalen-2-ol, C19H18N2O3
  50. Crystal structure of catena-poly[di(μ2-cyanido-κ2C:N)-dicyanido-tetrakis(dimethyl sulfoxide-κO)-manganese(II)-platinum(II)], C12H24MnN4O4PtS4
  51. Crystal structure of 4-amino-N-(2-pyrimidinyl)benzenesulfonamide–1,4-dioxane (1/1), C14H18N4O4S
  52. Crystal structure of bis{1-[(benzotriazol-1-yl)methyl]-1H-1,3-(2-methyl-imidazol)}di-chloridomercury(II), [Hg(C11H11N5)2Cl2], C22H22N10Cl2Hg
  53. Crystal structure of 2, 3-bis((4-methylbenzoyl)oxy) succinic acid–N, N-dimethylformamide (1/1), C23H25NO9
  54. Crystal structure of catena-poly[bis(4-(4-carboxyphenoxy)benzoato-κ1O)-μ2-(1,4-bis(1-imidazolyl)benzene-κ2N:N′)cobalt(II)], C40H28N4O10Co
  55. Crystal structure of 1H-imidazol-3-ium poly[aqua-(μ4-glutarato-κ6O,O′:O′:O′′,O′′′:O′′′)-(nitrato-κ2O,O′)strontium(II)], C8H13N3O8Sr
  56. Crystal structure of (R)-6-(benzo[b]thiophen-5-yl)-2-methyl-2,6-dihydrobenzo [5,6] silino[4,3,2-cd]indole, C23H17NSSi
  57. Crystal structure of catena-poly[bis(μ2-thiocyanato-κ2N:S)-(2-(5-methyl-1H-pyrazol-3-yl)pyridine-κ2N,N′)cadmium(II)]–dioxane (1/1), C15H17CdN5O2S2
  58. Crystal structure of poly[aqua-(μ2-1,4-bis(2′-carboxylatophenoxy)benzene-κ2O:O′)-(μ2-4,4′-bipyridione-κ2N:N′)cadmium(II)] monhydrate, C30H22CdN2O7⋅H2O
  59. Crystal structure of catena-poly[tetraaqua-(μ2-4,4′-bipyridine-k2N:N′)-bis(μ2-4′-methyl-[1,1′-biphenyl]-3,5-dicarboxylato-k4O,O′:O″,O′″)dicadmium(II)] dihydrate, C20H20NO7Cd
  60. Crystal structure of 1‐tert‐butyl‐3‐(2,6‐diisopropyl‐4‐phenoxyphenyl)‐2-methylisothiourea, C24H34N2OS
  61. Crystal structure of catena-poly[triaqua-(μ2-1,3-di(1H-imidazol-1-yl)propane-κ2N:N′)-(4,4′-(1H-1,2,4-triazole-3,5-diyl)dibenzoato-κ1O)cobalt(II)] — N,N′-dimethylformamide (1/1), C28H34N8O8Co
  62. Crystal structure of tetraaqua-bis(1,4-di(1H-imidazol-1-yl)benzene-κ1N)manganese(II) 2,3-dihydroxyterephthalate, C32H32MnN8O10
Heruntergeladen am 9.11.2025 von https://www.degruyterbrill.com/document/doi/10.1515/ncrs-2020-0617/html
Button zum nach oben scrollen